Comparison 10. Withdrawals ‐ febuxostat 80 mg/day versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 TOTAL	2	479	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [1.01, 1.97]
1.1 28 days	1	78	Risk Ratio (M‐H, Fixed, 95% CI)	1.43 [0.25, 8.06]
1.2 28 weeks	1	401	Risk Ratio (M‐H, Fixed, 95% CI)	1.41 [1.01, 1.98]
2 Adverse event	2	479	Risk Ratio (M‐H, Fixed, 95% CI)	1.82 [0.74, 4.46]
2.1 28 days	1	78	Risk Ratio (M‐H, Fixed, 95% CI)	1.9 [0.18, 20.10]
2.2 28 weeks	1	401	Risk Ratio (M‐H, Fixed, 95% CI)	1.81 [0.69, 4.76]
3 Gout flare	2	479	Risk Ratio (M‐H, Random, 95% CI)	2.22 [0.05, 101.12]
3.1 28 days	1	78	Risk Ratio (M‐H, Random, 95% CI)	0.32 [0.01, 7.55]
3.2 28 weeks	1	401	Risk Ratio (M‐H, Random, 95% CI)	13.60 [0.81, 227.06]
4 Lack of efficacy	2	479	Risk Difference (M‐H, Fixed, 95% CI)	0.00 [‐0.03, 0.03]
4.1 28 days	1	78	Risk Difference (M‐H, Fixed, 95% CI)	0.0 [‐0.05, 0.05]
4.2 28 weeks	1	401	Risk Difference (M‐H, Fixed, 95% CI)	0.00 [‐0.03, 0.03]
5 Other reasons	2	479	Risk Ratio (M‐H, Fixed, 95% CI)	1.15 [0.76, 1.75]
5.1 28 days	1	78	Risk Ratio (M‐H, Fixed, 95% CI)	2.85 [0.12, 67.97]
5.2 28 weeks	1	401	Risk Ratio (M‐H, Fixed, 95% CI)	1.12 [0.74, 1.72]